HC Wainwright Weighs in on Anixa Biosciences, Inc.’s FY2024 Earnings (NASDAQ:ANIX)

Anixa Biosciences, Inc. (NASDAQ:ANIX) – HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Anixa Biosciences in a note issued to investors on Monday, September 16th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.42) per share for the year, up from their previous forecast of ($0.43). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.46) EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Down 0.9 %

Anixa Biosciences stock opened at $3.42 on Wednesday. Anixa Biosciences has a 12-month low of $2.14 and a 12-month high of $5.13. The stock has a 50-day simple moving average of $3.16 and a 200 day simple moving average of $2.99. The stock has a market capitalization of $109.46 million, a price-to-earnings ratio of -9.14 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Friday, September 6th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Nations Financial Group Inc. IA ADV lifted its holdings in shares of Anixa Biosciences by 50.0% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after purchasing an additional 7,500 shares in the last quarter. Virtu Financial LLC boosted its stake in shares of Anixa Biosciences by 47.2% during the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after acquiring an additional 5,183 shares during the period. Concorde Asset Management LLC acquired a new position in shares of Anixa Biosciences in the second quarter valued at $31,000. Staley Capital Advisers Inc. acquired a new position in Anixa Biosciences in the 1st quarter valued at about $31,000. Finally, Simplicity Wealth LLC acquired a new position in shares of Anixa Biosciences in the first quarter valued at approximately $44,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 21,646 shares of the business’s stock in a transaction on Tuesday, July 30th. The shares were bought at an average cost of $3.06 per share, for a total transaction of $66,236.76. Following the transaction, the director now owns 890,754 shares in the company, valued at approximately $2,725,707.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 22.60% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.